SPECT/CT-plethysmography – non-invasive quantitation of bone and soft tissue blood flow

Preserved blood flow to bone and soft tissue is essential for their normal function. To date only numerous methods are suitable for direct bone blood flow (BBF) measurement. Here, we introduce a novel quantitative method for bone and soft tissue blood flow (BBF and SBF, respectively) measurement. It involves a combination of SPECT/CT imaging for blood pool localization in a specific region of interest ("soft" and "hard" tissues composing a limb) with veno-occlusive plethysmography. Using it, we measured BBF and SBF in the four limbs of 10 healthy subjects. At steady state blood flow measurements in the four limbs were similar, ranging between 5.5 – 6.5 and 1.87–2.48 ml per 100 ml of tissue per minute for BBF and SBF, respectively. Our results are comparable to those in the literature. We concluded that SPECT/CT-plethysmography appears to be a readily available and easy to use method to measure BBF and SBF, and can be added to the armamentarium of methods for BBF measurements

Monogenic Early-Onset Lymphoproliferation and Autoimmunity: The Natural History of STAT3 GOF Syndrome.

Background In 2014, germline signal transducer and activator of transcription (STAT) 3 gain-of-function (GOF) mutations were first described to cause a novel multisystem disease of early-onset lymphoproliferation and autoimmunity. Objective This pivotal cohort study defines the scope, natural history, treatment, and overall survival of a large global cohort of patients with pathogenic STAT3 GOF variants. Methods We identified 191 patients from 33 countries with 72 unique mutations. Inclusion criteria included symptoms of immune dysregulation and a biochemically confirmed germline heterozygous GOF variant in STAT3. Results Overall survival was 88%, median age at onset of symptoms was 2.3 years, and median age at diagnosis was 12 years. Immune dysregulatory features were present in all patients: lymphoproliferation was the most common manifestation (73%); increased frequencies of double-negative (CD4−CD8−) T cells were found in 83% of patients tested. Autoimmune cytopenias were the second most common clinical manifestation (67%), followed by growth delay, enteropathy, skin disease, pulmonary disease, endocrinopathy, arthritis, autoimmune hepatitis, neurologic disease, vasculopathy, renal disease, and malignancy. Infections were reported in 72% of the cohort. A cellular and humoral immunodeficiency was observed in 37% and 51% of patients, respectively. Clinical symptoms dramatically improved in patients treated with JAK inhibitors, while a variety of other immunomodulatory treatment modalities were less efficacious. Thus far, 23 patients have undergone bone marrow transplantation, with a 62% survival rate. Conclusion : STAT3 GOF patients present with a wide array of immune-mediated disease including lymphoproliferation, autoimmune cytopenias, and multisystem autoimmunity. Patient care tends to be siloed, without a clear treatment strategy. Thus, early identification and prompt treatment implementation are lifesaving for STAT3 GOF syndrome. Key word